New hope for Hard-to-Treat cancers: experimental drug SY-9453 enters human testing
Disease control
Recruiting now
This early-phase study tests a new drug called SY-9453 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 122 adults whose cancer has…
Phase: PHASE1 • Sponsor: Shouyao Holdings (Beijing) Co. LTD • Aim: Disease control
Last updated May 15, 2026 11:55 UTC